[The CUP syndrome--malignant disease with unknown primary tumor. Part 3: Metastatic site--tumor markers].
Multiple axillary-infraclavicular lymph node metastasis from malignant rhabdoid tumor of unknown primary site.
Genomic mapping of metastatic organotropism in lung adenocarcinoma.
Lengel HB, Mastrogiacomo B, Connolly JG, Tan KS, Liu Y, Fick CN, Dunne EG, He D, Lankadasari MB, Satravada BA, Sun Y, Kundra R, Fong C, Smith S, Riely GJ, Rudin CM, Gomez DR, Solit DB, Berger MF, Li BT, Mayo MW, Matei I, Lyden DC, Adusumilli PS, Schultz N, Sanchez-Vega F, Jones DR.
Cancer Cell. 2023 May 8;41(5):970-985.e3. doi: 10.1016/j.ccell.2023.03.018. Epub 2023 Apr 20.
Cancer of unknown primary site.
Vajdic CM, Goldstein D.
Aust Fam Physician. 2015 Sep;44(9):640-3.
Localization of Unknown Primary Site with (68)Ga-DOTATOC PET/CT in Patients with Metastatic Neuroendocrine Tumor.
Menda Y, O'Dorisio TM, Howe JR, Schultz M, Dillon JS, Dick D, Watkins GL, Ginader T, Bushnell DL, Sunderland JJ, Zamba GKD, Graham M, O'Dorisio MS.
J Nucl Med. 2017 Jul;58(7):1054-1057. doi: 10.2967/jnumed.116.180984. Epub 2017 Feb 2.
Cancer of unknown primary site.
Pavlidis N, Pentheroudakis G.
Lancet. 2012 Apr 14;379(9824):1428-35. doi: 10.1016/S0140-6736(11)61178-1. Epub 2012 Mar 12.
Diagnostic Approaches to Neuroendocrine Neoplasms of Unknown Primary Site.
Daoud T, Morani AC, Waters R, Bhosale P, Virarkar MK.
J Comput Assist Tomogr. 2024 Jul-Aug 01;48(4):588-600. doi: 10.1097/RCT.0000000000001548. Epub 2023 Oct 25.
Diagnostic Approaches to Neuroendocrine Neoplasms of Unknown Primary Site.
Berner AM, Pipinikas C, Ryan A, Dibra H, Moghul I, Webster A, Luong TV, Thirlwell C.
Neuroendocrinology. 2020;110(7-8):563-573. doi: 10.1159/000504370. Epub 2019 Oct 28.
Familial cancer of unknown primary.
Rassy E, Kattan J, Pavlidis N.
Int J Clin Oncol. 2019 Oct;24(10):1328-1331. doi: 10.1007/s10147-019-01491-1. Epub 2019 Jun 15.
Cancer of unknown primary site.
Ultmann JE.
J Cancer Res Clin Oncol. 1991;117(6):505-9. doi: 10.1007/BF01613279.
Cancer of unknown primary site and TNM staging: a new paradigm for patient management.
Anthony Greco F.
Ann Oncol. 2025 Nov;36(11):1299-1306. doi: 10.1016/j.annonc.2025.07.007. Epub 2025 Jul 21.
Risk factors and predictors for tumor site origin in metastatic adenocarcinoma of unknown primary site.
Li X, Shao Y, Sheng L, Zhu J, Wang Z, Guo K, Sun L.
Cancer Med. 2021 Feb;10(3):974-988. doi: 10.1002/cam4.3684. Epub 2021 Jan 6.
